Prelude Therapeutics Inc (PRLD): Total Liabilities
$72.68M
As of 2025-12-31
$55.63M
As of 2026-06-30
+42.6%
3-year compound annual growth
+44.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $72.68M | +65.0% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $44.06M | +8.6% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $40.58M | +61.9% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $25.06M | +30.5% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $19.20M | +68.3% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $11.41M | +135.7% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $4.84M | n/a | 2021-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $37.28M | -20.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗